cardiovascular benefits

Editor’s Note Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new class of oral hypoglycemic agents that primarily function by blocking the SGLT-2 transport protein in the proximal renal tubule, thereby promoting the excretion of glucose and sodium in urine.With the publication of cardiovascular outcome studies for these drugs, their cardiovascular benefits have been well established.Another … Read more